Boston Scientific has signed a deal to acquire the maker of a chemotherapy infusion pump aimed at treating certain inoperable ...

Intera makes a pump and a chemotherapy drug to treat liver tumors. Boston Scientific sees the purchase as a way to provide ...

Boston Scientific (NYSE:BSX) has agreed to acquire medical device maker Intera Oncology for an undisclosed amount, with the ...

The combination of chemotherapy and radioembolization appeared safe and effective in patients with well-differentiated, liver-dominant, grade 3 NETs.

A team of researchers led by Professor Ningling Kang, PhD, at The Hormel Institute, University of Minnesota, has published an ...

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study ...

The FDA approved a phase 3 trial to assess amezalpat with the current standard of care in unresectable or metastatic ...

The incidence of stomach cancer has been rising, with over 40% of patients presenting with metastases at the time of diagnosis. This trend underscores the importance of early detection and timely ...

Figure 2 Common sites of extrahepatic disease (arrows) considered for simultaneous resection are portal lymph nodes (A), lungs (B), and peritoneal metastases (C) Figure 3 Comparison of overall ...

The cancer cells that survive treatment become ... they can't adapt to the environment in the liver. Metastasis cells, on the other hand, can survive in both the colon and in the liver.